Nuveen LLC Takes $465,000 Position in Tyra Biosciences, Inc. $TYRA

Key Points

• Nuveen LLC has acquired a new stake in Tyra Biosciences, Inc., purchasing nearly 50,000 shares valued at approximately $465,000, which represents about 0.09% of the company's stock.
• Several institutional investors have significantly increased their holdings in Tyra Biosciences during the fourth quarter, with Janus Henderson Group PLC boosting its stake by 63.6% and Orbimed Advisors LLC by 91.3%.
• Tyra Biosciences recently reported an EPS of ($0.47) for the quarter, exceeding analysts’ expectations, and has a consensus price target of $31.43 based on ratings from multiple research analysts.

Nuveen LLC acquired a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 49,998 shares of the company's stock, valued at approximately $465,000. Nuveen LLC owned 0.09% of Tyra Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in TYRA. US Bancorp DE lifted its holdings in Tyra Biosciences by 50.5% during the 1st quarter. US Bancorp DE now owns 5,435 shares of the company's stock worth $51,000 after buying an additional 1,823 shares in the last quarter. Rhumbline Advisers boosted its holdings in Tyra Biosciences by 7.2% in the first quarter. Rhumbline Advisers now owns 28,081 shares of the company's stock valued at $261,000 after purchasing an additional 1,879 shares during the period. Wells Fargo & Company MN grew its stake in Tyra Biosciences by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock worth $132,000 after purchasing an additional 3,236 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in Tyra Biosciences by 42.7% during the 1st quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company's stock worth $110,000 after purchasing an additional 3,550 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Tyra Biosciences by 4.4% during the 4th quarter. Wellington Management Group LLP now owns 94,859 shares of the company's stock worth $1,319,000 after purchasing an additional 4,034 shares during the period. Institutional investors and hedge funds own 84.14% of the company's stock.

Tyra Biosciences Stock Up 0.8%

TYRA traded up $0.09 on Wednesday, reaching $11.91. The company had a trading volume of 184,549 shares, compared to its average volume of 226,710. The stock has a market capitalization of $634.80 million, a PE ratio of -6.69 and a beta of 1.10. Tyra Biosciences, Inc. has a 1 year low of $6.42 and a 1 year high of $29.60. The stock has a 50-day moving average price of $11.09 and a 200-day moving average price of $10.28.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.06. As a group, analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Gilla Kaplan sold 9,568 shares of the firm's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $9.78, for a total transaction of $93,575.04. Following the transaction, the director directly owned 28,231 shares of the company's stock, valued at approximately $276,099.18. This trade represents a 25.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 61,392 shares of company stock worth $628,358. 15.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Raymond James Financial assumed coverage on Tyra Biosciences in a research note on Tuesday, September 2nd. They issued a "strong-buy" rating and a $35.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, August 22nd. Piper Sandler started coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price target for the company. Finally, Oppenheimer restated an "outperform" rating and issued a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat.com, Tyra Biosciences presently has a consensus rating of "Buy" and an average price target of $31.86.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.